- Home
- PCVX vs ACLX Comparison
PCVX vs ACLX Comparison
Compare PCVX & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | ACLX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.7B |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PCVX | ACLX |
|---|---|---|
| Price | $49.89 | $115.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 15 |
| Target Price | $88.25 | ★ $118.17 |
| AVG Volume (30 Days) | 1.6M | ★ 12.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,286,000.00 |
| Revenue This Year | N/A | $342.39 |
| Revenue Next Year | N/A | $170.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.10 | $60.36 |
| 52 Week High | $65.00 | $115.14 |
Technical Indicators
Market Signals| Indicator | PCVX | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 39.93 | 79.86 |
| Support Level | $42.30 | $63.46 |
| Resistance Level | $56.04 | N/A |
| Average True Range (ATR) | 2.47 | 0.11 |
| MACD | -0.51 | -0.62 |
| Stochastic Oscillator | 34.37 | 84.28 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.